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Abstract
Aim To determine whether intermediate hyperglycaemia, defined by fasting plasma glucose and HbA1c criteria, is
associated with mortality in a 10-year cohort of people in a Latin American country.
Methods Analysis of the PERUMIGRANTStudywas conducted in three different population groups (rural, rural-to-urban
migrant, and urban).The baseline assessmentwas conducted in2007/2008,with follow-up assessment in 2018.The outcome
was all-cause mortality, and the exposure was intermediate hyperglycaemia, using three definitions: (1) impaired fasting
glucose, defined according to American Diabetes Association criteria [fasting plasma glucose 5.6–6.9 mmol/l (100–125 mg/
dl)]; (2) intermediate hyperglycaemia defined according to American Diabetes Association criteria [HbA1c levels 39–46
mmol/mol (5.7–6.4%)]; and (3) intermediate hyperglycaemia defined according to the International Expert Committee
criteria [HbA1c levels 42–46 mmol/mol (6.0–6.4%)]. Crude and adjusted hazard ratios and 95% CIs were estimated using
Cox proportional hazard models.
Results At baseline, the mean (SD) age of the study population was 47.8 (11.9) years and 52.5% of the cohort were
women. The study cohort was divided into population groups as follows: 207 people (20.0%) in the rural population
group, 583 (59.7%) in the rural-to-urban migrant group and 198 (20.3%) in the urban population group. The
prevalence of intermediate hyperglycaemia was: 6%, 12.9% and 38.5% according to the American Diabetes Association
impaired fasting glucose definition, the International Expert Committee HbA1c-based definition and the American
Diabetes Association HbA1c-based definition, respectively, and the mortality rate after 10 years was 63/976 (7%).
Intermediate hyperglycaemia was associated with all-cause mortality using the HbA1c-based definitions in the crude
models [hazard ratios 2.82 (95% CI 1.59–4.99) according to the American Diabetes Association and 2.92 (95% CI
1.62–5.28) according to the International Expert Committee], whereas American Diabetes Association-defined impaired
fasting glucose was not [hazard ratio 0.84 (95% CI 0.26–2.68)]. In the adjusted model, however, only the American
Diabetes Association HbA1c-based definition was associated with all-cause mortality [hazard ratio 1.91 (95% CI 1.03–
3.53)], whereas the International Expert Committee HbA1c-based and American Diabetes Association impaired fasting
glucose-based definitions were not [hazard ratios 1.42 (95% CI 0.75–2.68) and 1.09 (95% CI 0.33–3.63), respectively].
Conclusions Intermediate hyperglycaemia defined using the American Diabetes Association HbA1c criteria was
associated with an elevated mortality rate after 10 years in a cohort from Peru. HbA1c appears to be a factor associated
with mortality in this Peruvian population.
Diabet. Med. 37, 1519–1527 (2020)
Introduction
Type 2 diabetes mellitus is a major public health burden:
80% of cases are in low- and middle-income countries and
the economic burden and mortality rate are higher in these
settings than in high-income countries [1]. Intermediate
hyperglycaemia is an important risk factor for diabetes, but
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the proportion of people with this condition varies according
to the definition used [2]. The relevance of the term
‘intermediate hyperglycaemia’ is therefore debated because
of the arbitrary cut-off points used in its definition [3].
The association between diabetes and mortality is well
known and may vary according to age, cardiovascular
disease, renal complications and glycaemic control [4];
however, there is debate regarding the association of inter-
mediate hyperglycaemia and mortality. A systematic review
and meta-analysis including 53 cohorts, totalling more than
1.5 million individuals, found that intermediate hypergly-
caemia definitions that use impaired fasting glucose (IFG),
defined according to the American Diabetes Association
(ADA) criteria [fasting plasma glucose (FPG) 5.6–6.9 mmol/l
(100–125 mg/dl)] and WHO criteria [FPG 6.1–6.9 mmol/l
(110–125 mg/dl)], or use impaired glucose tolerance [IGT,
defined as 2-h plasma glucose 7.8–11.0 mmol/l (140–199 mg/
dl)] were associated with all-cause mortality. This was not
the case when the ADA HbA1c-based [HbA1c: 39–47 mmol/
mol (5.7–6.4%)] or the International Expert Committee
(IEC) HbA1c-based definitions of intermediate hypergly-
caemia [HbA1c 42–47 mmol/mol (6.0–6.4%)] were used
[5]. In addition, a study in Taiwan found that IFG defined
according to the WHO was associated with an increase in
cardiovascular disease and/or diabetes mortality; however,
using the ADA’s definition of IFG, the number of people was
four times greater, but there was a lower mortality risk [6].
As far as we are aware, no study has reported on the
association of intermediate hyperglycaemia with mortality in
a Latin American country. However, recent studies have
highlighted the higher mortality risk attributable to type 2
diabetes in Latin American countries compared to high-
income countries, as shown in a recent systematic review [7].
It is therefore important to assess whether impaired fasting
glucose, impaired glucose tolerance or intermediate hyper-
glycaemia, defined according to HbA1c levels, are associated
with mortality in these populations. The results of the present
study should contribute to the worldwide evidence of
intermediate hyperglycaemia and its relevance as a predictor
of mortality. The aim of this study was to determine the
association of intermediate hyperglycaemia status, assessed
using three different definitions (IFG based on the ADA
criteria, the ADAHbA1c-based definition and the IEC HbA1c-
based definition), with 10-year mortality in a Latin American
country. Additionally, we explored the associations of
different definitions of type 2 diabetes with mortality.
Methods
Study design, setting and participants
A new analysis of the PERU MIGRANT Study was
conducted to evaluate mortality 10 years after baseline.
The baseline assessment was conducted in 2007–2008 and
the follow-up in 2018.
The study population was categorized into three groups:
urban, rural-to-urban migrants, and rural. A single-stage
random sampling method was used in the three population
groups and the sample was stratified by sex and age (30–39,
40–49, 50–59 and ≥60 years). Urban participants were born
and currently lived in Pampas de San Juan de Miraflores, a
peri-urban shantytown in Lima, the capital city, during the
baseline assessment. Rural participants were selected from
the adult population permanently living in San Jose de Secce
in Ayacucho (3239 m above sea level). Rural-to-urban
migrants lived in Pampas de San Juan de Miraflores and
were born in Ayacucho, Peru. There was no overlap between
the three population groups as the selection criteria were
based on two factors: (1) place of birth and (2) place of
residence.
The PERU MIGRANT Study settings and the character-
istics of the enrolled participants have been described in
detail elsewhere [8].
Follow-up assessment
At the 10-year follow-up the vital status of participants (dead
or alive) was recorded using their National Identifier Num-
ber, which was verified in the national records using the
National Registry of Identification and Civil Status
(RENIEC) information. For this assessment, surviving par-
ticipants were not directly contacted as only vital status and
date of death or censoring was required. If a participant had
died, the date of death was used, if the participant was alive,
then the date on which the search was conducted was
considered as the censoring date.
Variables definition
All-cause mortality was the outcome of interest and was
defined by the occurrence of any fatal event at any point
during the 10 years of follow-up. Vital status and exact date of
What’s new?
• Intermediate hyperglycaemia is an important risk factor
for diabetes, but the proportion of people with this
condition varies according to the definition used.
• The extent to which impaired fasting glucose, impaired
glucose tolerance and/or HbA1c criteria are associated
with mortality remains unclear.
• Intermediate hyperglycaemia assessed using the HbA1c-
based American Diabetes Association definition was
associated with increased mortality rate in a 10-year
cohort from a Latin American country.
• HbA1c appeared to be a measurement associated with
mortality in this Peruvian population.
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death were obtained by reviewing records provided by
RENIEC. In this follow-up, data obtained from participants
with a valid national identity document observable in the
RENIEC system were assessed. Vital status was then catego-
rized as ‘alive’ or ‘dead’, and the time between baseline and
the date of death or censorship was estimated in years.
The exposure of interest was intermediate hyperglycaemia,
measured at baseline, and assessed using the three different
definitions: (1) ADA-defined IFG [FPG 5.6–6.9 mmol/l (100–
125 mg/dl)] [9]; (2) the ADA HbA1c-based definition [HbA1c
39–46 mmol/mol (5.7–6.4%)] [9]; and (3) the IEC HbA1c-
based definition [ HbA1c 42–46 mmol/mol (6.0–6.4%)] [10].
Each definition also included a threshold above which
participants were classified as having type 2 diabetes, and
this group was added to those participants who self-reported
physician-diagnosed type 2 diabetes and those receiving
glucose-lowering drugs (Table 1) [10].
Other participant characteristics, measured at baseline,
that were included in the analysis as potential confounders
were age (four categories: 30–39, 40–49, 50–59 and ≥ 60
years), gender (male and female), and education level (< 7
years and ≥7 years). Socio-economic status was assessed
through a wealth index based on the possession of household
resources and household facilities (radio, types of television,
refrigerator, computer, telephone, mobile phone, internet,
cable television, motorcycle, car and gas cooker), and was
divided into tertiles (low, middle and high socio-economic
status). Population group included rural, rural-to-urban
migrant and urban categories. Current daily smoking (self-
reported smoking of at least one cigarette per day), alcohol
intake (self-reported low or high consumption based on the
number of bottles of beer or equivalent), and physical
activity levels, were also assessed. The latter variable was
categorized according to the International Physical Activity
Questionnaire as high/moderate if the participant performed
≥5 days of any combination of walking, moderate-intensity,
or vigorous-intensity activities achieving at least 600 meta-
bolic equivalent of task units (MET; multiples of the resting
metabolic rate) min/week, or low if the participant per-
formed < 600 MET min/week.
Obesity status was defined according to BMI (not obese:
BMI ≥18.5 and < 30 kg/m2; obese: BMI ≥30 kg/m2) [11].
Hypercholesterolaemia was defined by a total cholesterol
level ≥ 5.2 mmol/l (200 mg/dl) [12]. Finally, blood pressure
was measured after a 5-min resting period, with the
participant in a seated position. Three measurements, at
least 5 min apart, were carried out, and the mean of the
second and third measurements was taken. Hypertension
was defined as systolic blood pressure ≥ 140 mmHg or
diastolic blood pressure ≥ 90 mmHg, or was determined by
self-report of physician diagnosis and current receipt of anti-
hypertensive medication.
Finally, we estimated homeostatic model assessment
index for insulin resistance (HOMA-IR) using the formula
developed by Matthews [13] and categorized these into
tertiles (low, middle and high).
Laboratory procedures
Laboratory assessments were performed on venous samples
taken in the morning after a minimum of 8 h of fasting.
Fasting glucose was measured in plasma using a Cobas
Modular Platform automated analyser and reagents were
supplied by Roche Diagnostics (Grenzach-Whylen, Germany).
Serum total cholesterol was measured and HbA1c was
measured in whole blood using high-performance liquid
chromatography (D10; BioRad, Munich, Germany), traceable
to the Diabetes Control and Complications Trial reference
study, as certified by the National Glycohaemoglobin Stan-
dardization Programme [14]. All samples were analysed at a
single facility, and, for quality assurance, assay results were
checked with regular external standards and internal duplicate
assays and monitored by BioRad (www.biorad.com) [8].
Statistical analysis
All statistical analyses were performed using STATA 14.0
(StataCorp, College Station, TX, USA). Prevalence and 95%
CIs of different hyperglycaemia categories were determined
overall. Mean and SD values for continuous variables and
proportions for categorical ones were used to describe
variables. The association of different hyperglycaemia cate-
gories and characteristics of the study population at baseline
were estimated using chi-squared tests.
For the incidence analysis, all-cause mortality rates were
calculated using incidence rates (the number of failures
divided by the person-time per 1000). Time to event was
estimated using the day of death and the log-rank test was
used to compare survival function using different factors
(sex, age, education level, socio-economic status, population
group, daily smoking habit). To study the association of
Table 1 Definitions of normal glycaemia, intermediate hyperglycaemia










































ADA, American Diabetes Association; FPG, fasting plasma
glucose; IEC, International Expert Committee; IFG, impaired
fasting glucose.
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intermediate hyperglycaemia, using each of the three defini-
tions, with mortality, crude and adjusted hazard ratios (HRs)
and 95% CIs were estimated using Cox proportional hazard
models. We used the test of proportional hazards assumption
(Schoenfeld residuals) in each model. Variables representing
potential confounders were selected by theory using the
directed acyclic graph (Fig. S1) and three models were used
to estimate HRs and their respective 95% CIs. In addition, a
sensitivity analysis was conducted by excluding those with a
previous type 2 diabetes diagnosis at baseline.
Ethics
All participants were informed about the objectives of the
study and oral informed consent was obtained owing to high
illiteracy rates, especially in rural areas. The institutional
review board of Universidad Peruana Cayetano Heredia in
Peru (Code: 51103) and of the London School of Hygiene
and Tropical Medicine in the UK approved the protocol for
the baseline assessment, and the follow-up phase was
approved by the Universidad Peruana Cayetano Heredia
institutional review board (Code: 64904).
Results
A total of 988 individuals were enrolled at baseline. The
mean (SD) age was 47.8 (11.9) years, 52.5% were women and
the population groups comprised the following: rural: 207
individuals (20.0%); rural-to-urban migrant: 583 individuals
(59.7%); and urban: 198 individuals (20.3%).
Characteristics of the study population, stratified by vital
status
At baseline, the prevalence rates of intermediate hypergly-
caemia were 6% (95% CI 5–8), 12.9% (95% CI 10.9–15.2)
and 38.5% (95% CI 35.5–41.6) using the ADA IFG-based,
IEC HbA1c-based, and ADA HbA1c-based definitions,
respectively. The prevalence of type 2 diabetes mellitus was
4% (95% CI 3–5) using the ADA FPG-based definition,
whereas using the ADA and IEC HbA1c-based definitions it
was 6% (95% CI 5–8). Cross-table analysis of the ADA IFG-
based and the ADA HbA1c-based definitions of normal
glycaemia, intermediate hyperglycaemia and type 2 diabetes,
and the respective ADA IFG-based and IEC HbA1c-based
definitions are shown in Table S1.
Some factors such as age, population group, obesity,
hypercholesterolaemia and hypertension were associated
with intermediate hyperglycaemia using the three definitions.
There was an association between gender and intermediate
hyperglycaemia using both the ADA IFG-based and the ADA
HbA1c-based definitions, and an association with education
level was additionally observed using both the ADA and IEC
HbA1c-based definitions (Table 2).
Characteristics of the study population, stratified by death
during follow-up
Data on the vital status of 976 participants were retrieved
from the RENIEC system. A total of 63 deaths were
recorded, with an all cause-mortality rate of 7 per 1000
person-years (95% CI 5–8). Crude analysis of mortality and
the characteristics of the study population showed strong
evidence of associations between mortality and male gender,
being older, having a lower education level, having a lower
socio-economic status, and having hypertension (Table S2).
Association between glucose and HbA1c status and overall
mortality
Intermediate hyperglycaemia was associated with 10-year
all-cause mortality using the HbA1c-based definitions in the
crude models, with an almost threefold higher rate in
comparison to normal HbA1c levels (Kaplan–Meier curves
are shown in Fig. S2). However, in the adjusted models, only
the ADA HbA1c-based definition was associated with all-
cause mortality; participants with intermediate hypergly-
caemia according to this definition had a mortality rate
almost twice as high in comparison to those with normal
HbA1c levels.
There was no evidence of an association between the ADA
IFG-based definition of intermediate hyperglycaemia and
mortality, either in the crude or the adjusted model (Table 3).
However, although the association between type 2 dia-
betes and 10-year mortality was significant in the adjusted
models using all three definitions, the strength of association
varied from an HR of 2.92 (95% CI 1.18–7.22) using the
FPG-based ADA definition, to an of HR 5.31 (95% CI 2.34–
12.05) using the HbA1c-based ADA definition.
In the sensitivity analysis, which excluded those with a
previous diagnosis of type 2 diabetes, the results were
consistent, with slight changes in HR estimates (Table S3).
Association between glucose and HbA1c status and overall
mortality, stratified by population group
The analysis according to population group showed an
association between intermediate hyperglycaemia and all-
cause mortality using the ADA HbA1c-based definition in the
rural and rural-urban migrant groups, but not in the urban
group. The association in the rural group was four times
greater, while the association in the rural-to-urban migrant
group was 2.5 times greater. Using the IEC HbA1c-based
definition, the association was significant only in the rural-to-
urban migrant group (Table 4).
The association between type 2 diabetes and mortality was
significant using both the ADA and the IEC HbA1c-based
definitions in the three groups; however, the association in
the rural group was 9.6 times greater, whereas in the rural-
to-urban migrant and the urban groups it was 4.8 and 5.7
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times greater, respectively, using the ADA HbA1c-based
definition.
Discussion
Given that there are several different definitions of interme-
diate hyperglycaemia, and that these use arbitrary cut-off
points, further studies of these definitions and their associ-
ations with patient-important outcomes are relevant. The
present study adds to the literature by assessing mortality
rates among individuals with intermediate hyperglycaemia
using population-based data. The prevalence of intermediate
hyperglycaemia according to the three studied definitions
varied from 5.9% to 38.5%. The study also found that
individuals with HbA1c levels between 39 and 46 mmol/mol
(5.7 and 6.4%) had a higher rate of mortality in comparison
to people with HbA1c levels < 39 mmol/mol (5.7%) in this
cohort from Peru, at 10-year follow-up. The IEC HbA1c-
based definition was associated with an increased risk of
mortality, although this was not statistically significant.
There was no evidence of an association between the ADA
IFG-based definition of intermediate hyperglycaemia and
mortality, but such an observation was observed when using
the ADA HbA1c-based definition, although participants with
intermediate hyperglycaemia according to the latter defini-
tion did have a somewhat more favourable car-
diometabolic risk profile, especially with regard to obesity.
Our findings differ from those of a systematic review and
meta-analysis by Huang et al. [5] who reported that
intermediate hyperglycaemia defined by fasting glucose level
Table 2 Baseline characteristics of the study population, stratified according to normal glycaemia, intermediate hyperglycaemia and type 2 diabetes



















(n = 879) (n = 58) (n = 39) (n = 543) (n = 376) (n = 57) (n = 793) (n = 126) (n = 57)
Men, n (%) 426 (48.5) 18 (31.0) 20 (51.3) 283 (52.1) 155 (41.2) 26 (45.6) 380 (47.9) 58 (46.0) 26 (45.6)
Age, n (%)
30–39 years 264 (30.0) 11 (19.0) 6 (15.4) 209 (38.5) 65 (17.3) 7 (12.3) 261 (32.9) 13 (10.3) 7 (12.3)
40–49 years 257 (29.2) 15 (25.9) 6 (15.4) 165 (30.4) 102 (25.1) 11 (19.3) 239 (30.1) 28 (22.2) 11 (19.3)
50–59 years 225 (25.6) 24 (41.4) 20 (51.3) 115 (21.2) 128 (34.0) 26 (45.6) 199 (25.1) 44 (34.9) 26 (45.6)




453 (51.6) 30 (52.6) 20 (51.3) 309 (57.0) 170 (45.3) 24 (42.1) 429 (54.2) 50 (39.7) 24 (42.1)
Socio-economic status, n (%)
Low 386 (43.9) 23 (39.6) 15 (38.4) 215 (39.6) 185 (49.2) 24 (42.1) 340 (42.9) 60 (47.6) 24 (42.1)
Middle 207 (23.6) 19 (32.8) 12 (30.8) 141 (26.0) 83 (22.1) 14 (24.6) 201 (25.4) 23 (18.3) 14 (24.6)
High 286 (32.5) 16 (27.6) 12 (30.8) 187 (34.4) 108 (28.7) 19 (33.3) 252 (31.8) 43 (34.1) 19 (33.3)
Population group, n (%)
Rural 188 (21.4) 4 (6.9) 3 (7.7) 95 (17.5) 85 (22.6) 15 (26.3) 147 (18.5) 33 (26.2) 15 (26.3)
Rural-urban migrant 533 (60.6) 30 (51.7) 20 (51.3) 362 (66.7) 195 (51.9) 26 (45.6) 499 (62.9) 58 (46.0) 26 (45.6)
Urban 158 (18.0) 24 (41.4) 16 (41.0) 86 (15.8) 96 (25.5) 16 (28.1) 147 (18.5) 35 (27.8) 16 (28.1)
Daily smoking
habit, n (%)
30 (3.4) 1 (1.7) 2 (5.1) 12 (2.2) 19 (5.1) 2 (3.5) 24 (3.0) 7 (5.6) 2 (3.5)
High alcohol
consumption, n (%)




220 (25.2) 20 (34.5) 12 (31.6) 142 (26.4) 94 (25.2) 16 (28.6) 206 (26.2) 30 (23.8) 16 (28.6)




265 (30.2) 19 (32.8) 20 (51.3) 149 (27.5) 129 (34.3) 26 (45.6) 230 (29.0) 48 (38.1) 26 (45.6)
Hypertension,
n (%)
126 (14.4) 16 (27.6) 13 (33.3) 58 (10.7) 82 (21.8) 15 (26.3) 105 (13.3) 35 (27.8) 15 (26.3)
HOMA-IR index, n (%)
Low 319 (36.7) 3 (5.2) 1 (2.6) 201 (37.2) 113 (30.5) 9 (16.1) 276 (35.1) 38 (30.7) 9 (16.1)
Middle 310 (35.6) 8 (13.8) 4 (10.3) 210 (38.9) 102 (27.5) 10 (17.9) 279 (35.4) 33 (26.6) 10 (17.9)
High 241 (27.7) 47 (81.0) 34 (87.2) 129 (23.9) 156 (42.1) 37 (66.1) 232 (29.5) 53 (42.7) 37 (66.0)
ADA, American Diabetes Association; HOMA-IR, homeostatic model assessment index for insulin resistance; IEC, International Expert
Committee; IFG, impaired fasting glucose.
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was associated with all cause-mortality, but they did not find
an association using the HbA1c definitions [5]. Similar to our
results, however, a previous systematic review by the same
author group [15], as well as a study from Taiwan [6],
reported no association between intermediate hypergly-
caemia, assessed using the ADA IFG-based definition, and
all-cause mortality and cardiovascular disease and/or
diabetes mortality. It is important to mention that, in the
recent systematic review [5], only the studies conducted in
the Netherlands and Finland, and not in other countries,
reported a strong association between ADA IFG-defined
intermediate hyperglycaemia and all-cause mortality. In
addition, only studies from the USA, Asia, Europe and
Australia were included in the systematic review, and it did
not include, for example, individuals with different sociode-
mographic and lifestyle characteristics from those living in
Latin America. Genetics might play a role in the difference
among findings worldwide: the admixture among Peruvians
is very high, with many groups sharing common Native
American ancestry [16], whereas the European ancestry
component is relatively small (<10%) [17].
The correlation between glucose and HbA1c levels might
also play a role in the differences between the findings of
the present study when compared to those of the previous
systematic reviews as these variables are affected by factors
such as high altitude [18], environmental temperature [19],
or the characteristics of the tests themselves [20]. In
addition, high altitude could explain the fact that the HRs
for the associations between both intermediate hypergly-
caemia and type 2 diabetes with mortality were higher in
the rural population in comparison to the rural-to-urban
migrant and urban populations; a previous study in Peru
found that 53 mmol/mol (6.5%) of HbA1c was correlated
to glucose levels of 6.6. mmol/l at sea levels and 14.8 mmol/
l at high altitude. Furthermore, in India, a lower HbA1c
threshold has been used to define diabetes [45 mmol/mol
(6.3%)], based on the glucose torelance test [21], which
highlights the fact that some participants in the present
study might have been misclassified as having intermediate
hyperglycaemia using HbA1c, when in reality, they have
type 2 diabetes mellitus.
Table 3 Association between overall mortality and normal, intermediate hyperglycaemia and type 2 diabetes: crude and adjusted models
Deaths, n/N (%)
Crude model Adjusted model 1* Adjusted model 2† Adjusted model 3‡
HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI)
ADA IFG-based definition
Normal 54/879 (6.1) 1 (Reference) 1 (Reference) 1 (Reference) 1 (Reference)
Intermediate hyperglycaemia 3/58 (5.2) 0.84 (0.26–2.68) 0.85 (0.27–2.74) 1.01 (0.31–3.26) 1.09 (0.33–3.63)
Type 2 diabetes 6/39 (15.4) 2.62 (1.13–6.08) 2.14 (0.91–5.00) 2.15 (0.89–5.17) 2.92 (1.18–7.22)
ADA HbA1c-based definition
Normal 18/543 (3.3) 1 (Reference) 1 (Reference) 1 (Reference) 1 (Reference)
Intermediate hyperglycaemia 34/376 (9.0) 2.82 (1.59–4.99) 1.91 (1.07–3.43) 1.81 (1.01–3.27) 1.91 (1.03–3.53)
Type 2 diabetes 11/57 (19.3) 6.25 (2.95–13.24) 4.08 (1.90–8.75) 3.82 (1.74–8.37) 5.31 (2.34–12.05)
IEC HbA1c-based definition
Normal 36/793 (4.5) 1 (Reference) 1 (Reference) 1 (Reference) 1 (Reference)
Intermediate hyperglycaemia 16/126 (12.7) 2.92 (1.62–5.28) 1.46 (0.80–2.66) 1.34 (0.73–2.48) 1.42 (0.75–2.68)
Type 2 diabetes 11/57 (19.3) 4.53 (2.31–8.91) 3.07 (1.55–6.07) 2.86 (1.41–5.77) 3.89 (1.88–8.05)
ADA, American Diabetes Association; HR, hazard ratio; IEC, International Expert Committee; IFG, impaired fasting glucose.
The test of proportional hazards assumption was applied and we cannot reject the null hypothesis that the hazards are proportional.
Bold values represent estimates with P-values <0.05 .
*Adjusted for sex, age.
†Adjusted for sex, age, education level, socio-economic status, population group.
‡Adjusted for sex, age, education level, socio-economic status, population group, daily smoking, alcohol use, physical activity,
hypercholesterolaemia, hypertension and obesity.
Table 4 Association between overall mortality and normal glycaemia,
intermediate hyperglycaemia and type 2 diabetes according to rural,













1 (Reference) 1 (Reference)
Intermediate
hyperglycaemia
- 1.27 (0.30–5.33) 0.72 (0.09–
5.69)
Type 2 diabetes 5.16 (0.69–
38.85)










2.52 (1.20–5.34) 2.17 (0.56–
8.40)
Type 2 diabetes 9.68 (1.21–
15.61)










4.34 (1.97–9.60) 2.94 (0.82–
10.40)
Type 2 diabetes 3.97 (1.26–
12.48)
4.23 (1.44–12.46) 4.81 (1.20–
19.25)
ADA, American Diabetes Association; HR, hazard ratio; IEC,
International Expert Committee; IFG, impaired fasting glucose.
Bold values represent estimates with P-values <0.05 .
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As mentioned in the introduction, the association between
type 2 diabetes mellitus and all-cause mortality is well
known; however, the estimations of the associations in the
present study (HRs of 2.92–5.30 according to the different
definitions) are higher in comparison to those in previous
studies. The relatively recent systematic review of all-cause
mortality among individuals with type 2 diabetes in Latin
America found a relative risk of between 2.26 (95% CI 1.36–
3.74) and 2.49 (95% CI 1.96–3.15) using a composite
definition and self-reported diagnosis, respectively [7]. The
highest association observed in the systematic review was an
HR of 6.64 (95% CI 1.94–22.8) in a cohort in Brazil with 13
years of follow-up [22], and another high value was the HR
of 4.38 (95% CI 3.43–5.59) reported in a cohort in Mexico
with a 15-year follow-up [23]. These are greater than the
associations of mortality and type 2 diabetes found in
Sweden (adjusted HR 1.15, 95% CI 1.14–1.16) in a cohort
with a 4-year follow-up, [4] and in England (adjusted HR
2.19, 95% CI 2.16–2.21) in a cohort followed for 17 years
[24]. The differences between high-income countries and
countries in Latin America may be the result of disparities in
access to healthcare, insurance coverage, and the quality of
healthcare received between such countries [25].
The findings of the present study are relevant as individuals
with HbA1c between 39 and 46 mmol/mol (5.7% and 6.4%)
had higher mortality than those with normal HbA1c levels,
showing that the former probably require special manage-
ment to prevent negative outcomes. However, a systematic
review including individuals with intermediate hypergly-
caemia found that screening and treatment strategies to
prevent type 2 diabetes mellitus had limitations because even
if both short- (6 months) and long-term (up to 7 years)
interventions delayed the onset of type 2 diabetes, many
individuals might have been incorrectly classified as having
intermediate hyperglycaemia [26]. Nowadays, lifestyle inter-
ventions are the standard of care for impaired glucose
tolerance [27], but there is limited evidence for these in the
management of IFG or intermediate hyperglycaemia defined
according to HbA1c levels. Moreover, the management of
intermediate hyperglycaemia with drugs is still controversial
in terms of efficacy and cost [28,29].
Finally, previous studies have found that the prevalence of
intermediate hyperglycaemia increases four times using the
ADA definitions (based on IFG and/or HbA1c) [6,30], which
could imply a huge challenge to health systems. Similarly,
another study in Peruvian population found that the mag-
nitude of regression to normal glucose/HbA1c levels was
much higher than progression towards type 2 diabetes after
2.5 years of follow-up [31]. So, even if we know that the
ADA HbA1c-based definition of intermediate hyperglycaemia
is associated with a high mortality rate, the available
evidence is not clear on how to manage this risk to prevent
progression to type 2 diabetes and/or mortality.
To date, nearly all efforts to synthesize the evidence
regarding intermediate hyperglycaemia have concentrated on
high-income countries. In the present study, we show that
intermediate hyperglycaemia using the ADA HbA1c-based
definition may be important for estimating the rate of
mortality in resource-constrained settings, contributing to
the knowledge in this area in a poorly studied population.
The study has some limitations that should be noted. First,
all-cause mortality was used as the outcome because infor-
mation about cause of death was not available using the
RENIEC records. Second, a potential time gap between the
date of death and its registration in RENIEC is possible and,
which could have led us to underestimate the incidence of
death in our population. Additionally, the factors identified
as associated with mortality (Table S3) were not adjusted for
confounders. Third, we could not include the WHO defini-
tion of IFG [FPG 6.1–6.9 mmol/l (110–125 mg/dl)] because
we did not have cases with that definition in our sample.
Fourth, an oral glucose tolerance test was not performed at
baseline for logistical and budget reasons. However, we
based our definition on the use of fasting glucose and HbA1c
as in previous studies. Fifth, our study population was not
nationally representative; however, it included different
population groups (rural, rural-to-urban migrants and
urban) from specific areas of Peru. Finally, HbA1c is usually
a specific measurement by which to diagnose and monitor
diabetes, but other conditions could increase HbA1c levels,
such as iron deficiency anaemia, a condition that might be
more common in rural areas or in people of low socio-
economic status. Additionally, other less common conditions
in Peru could affect HbA1c levels, such as kidney failure, liver
disease, sickle cell disease and thalassaemia [9].
In conclusion, intermediate hyperglycaemia using the ADA
HbA1c-based definition was associated with an increased
mortality rate in cohort from Peru with a 10-year follow-up.
HbA1c would appear to be a variable associated with
mortality in this Peruvian population. Further research is
needed, however, on how to prevent progression to type 2
diabetes and/or mortality in this population.
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